Janux Therapeutics(JANX) - 2023 Q4 - Annual Results

Exhibit 99.1 Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights SAN DIEGO, March 8, 2024 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended Decemb ...